E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with type II diabetes with nephropathy |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10047065 |
E.1.2 | Term | Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary to compare the reduction of albuminuria between treatment groups in patients with type 2 diabetes and micro- or macroalbuminuria |
|
E.2.2 | Secondary objectives of the trial |
Secondary i to compare the MCP-1 urinary levels between treatment groups, ii to compare the rate of remission from micro- to normo- and from macro- to microalbuminurua in the two treatment group; iii to correlate the MCP-1 urinary levels and UAE within treatment groups iv to detect any relationship between degree of UAE reduction and serum lipids profile within treatment groups; v to evaluate the comparative safety and tolerability of bindarit in association with irbesartan |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Patients may be enrolled under the following circumstances males and females patients with no limitation of race, aged 30 to 70 years; Type 2 diabetes defined as 30 years of age at diagnosis; insulin not required within 6 months of initial diagnosis; no history of diabetic ketoacidosis; currently treated with diet, oral hypoglycemics or insulin Brenner 2000 ; microalbuminuria defined as urinary albumin excretion, 20 to 200 g/min in at least 2 of 3 overnight urine samples or macroalbuminuria defined as urinary albumin excretion, 200 g/min in at least 2 of 3 overnight urine samples, confirmed in the baseline collection; should baseline albuminuria data not to be available, the patient may be conditionally treated; glycosylated haemoglobin Hb A1c 12 Brenner 2000 ; serum creatinine 8804; 3 mg/dL; normotensive patients or hypertensive patients on stable antihypertensive therapy over the last 3 months and without specific contraindications to angiotensin antagonist therapy; female patients of childbearing potential required to have a negative pregnancy test and use an approved birth control method; written informed consent to the trial signed and dated by the patient. |
|
E.4 | Principal exclusion criteria |
Patients cannot enter the trial under the following circumstances patients hypersensitive or allergic to ARBs, or with a positive history for drug allergy; Type 1 diabetes Brenner 2000 ; history of non diabetic renal disease, including renal artery stenosis Brenner 2000 ; history of heart failure before enrolment Brenner 2000 ; acute myocardial infarction, coronary artery bypass grafting within the past one month Brenner 2000 ; cerebral vascular accident or coronary angioplasty within the past six months month Brenner 2000 ; Transient Ischemic Attacks TIA in the past 12 months Brenner 2000 ; primary aldosteronism or pheocromocytoma Brenner 2000 ; severe uncontrolled hypertension sitting diastolic blood pressure 115 and/or sitting systolic blood pressure 220 mm Hg in the previous 6 months; chronic use of corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, MAO inhibitors; patients under the influence of alcohol or narcotics; patients treated with experimental drugs in the previous 4 weeks. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary to compare the reduction of albuminuria between treatment groups in patients with type 2 diabetes and micro- or macroalbuminuria |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |